Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

BetterLife PharmaCSE: BETR

1 Drug Candidate

BetterLife Pharma (CSE: BETR / OTC: BETRF) is a Canadian biotech developing BETR-001, a first-in-class non-hallucinogenic LSD derivative (2-bromo-LSD / BOL-148) for MDD, anxiety, and neuropathic pain. BETR-001 was acquired from Transcend Biodynamics LLC and activates the 5-HT2A receptor at 60% efficacy — sufficient for neuroplastogenic antidepressant effects but below the threshold for hallucinogenic effects. A composition of matter patent was granted January 2025, IND filing projected H1 2026.

Drug Pipeline

1

BETR-001 (BOL-148 / 2-bromo-LSD)

LSD
Pre-clinical
Major Depressive Disorder (MDD)Anxiety DisordersChronic Pain

Non-hallucinogenic 5-HT2A partial agonist (60% efficacy). Neuroplastogen. Composition of matter patent granted Jan 2025. IND-enabling studies completed; IND filing H1 2026. No tolerance with repeated dosing.

Quick Facts

Type
Public Biotech
Ticker
CSE: BETR
Lead Stage
Pre-clinical
Website
Visit